<DOC>
	<DOCNO>NCT02166177</DOCNO>
	<brief_summary>'ThRIL ' aim explore feasibility , safety efficacy TR002 , regulatory cell therapy , adjunct immunosuppressive treatment context liver transplantation</brief_summary>
	<brief_title>Safety Efficacy Study Regulatory T Cell Therapy Liver Transplant Patients</brief_title>
	<detailed_description>Stage I : To evaluate safety administer TR002 liver transplant recipient . Stage II : To evaluate efficacy TR002 administration allow discontinuation immunosuppressive therapy liver transplant recipient .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>End Stage Liver Disease</mesh_term>
	<criteria>Able give inform consent adult patient endstage liver disease list primary liver transplant ; calculate MELD score â‰¤ 25 time transplantation HIV RNApositive Hepatitis C Virus infection ; autoimmune liver disease previous organ transplant Ebstein Virus and/or Cytomegalovirus seronegativity chronic use systemic immunosuppressant hepatocellular carcinoma outside Milano criterion leukocytes &lt; 1.5x10^9/L and/or platelet &lt; 50x10^9/L .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>